Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Thursday, August 28, 2025, according to the funds’ daily disclosures. The moves highlight ARK’s ongoing confidence in the biotechnology sector, with fresh buying in gene-editing player Intellia Therapeutics (NTLA). At the same time, ARK trimmed its positions in TV streaming giant Roku (ROKU) and online sports betting operator DraftKings (DKNG).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wood Extends Selling in Roku and DraftKings
The biggest move of the day came from the sale of Roku shares. ARK’s flagship ARK Innovation ETF (ARKK) offloaded 55,624 shares, worth about $5.35 million, extending a selling streak that has lasted throughout the past week. The repeated trimming suggests ARK may be pulling back from the streaming device company after years of heavy exposure.
ARK also cut its stake in DraftKings, selling 54,679 shares across three funds — the ARKK, ARK Next Generation Internet ETF (ARKW), and ARK Fintech Innovation ETF (ARKF) — for about $2.61 million. The sale continues a pattern of reduced exposure this week, pointing to a possible reallocation away from digital sports betting and gaming.
In terms of performance, Roku and DraftKings shares have gained 31.2% and 29.7% year-to-date, respectively.
Wood Boosts Biotech Bet with Intellia Purchase
Meanwhile, ARK leaned into biotech with its largest purchase of the day: Intellia Therapeutics. The ARKK ETF added 349,930 Intellia shares worth about $4.0 million.
Intellia, a leader in gene-editing technology, has been a consistent buy for ARK in recent weeks, signaling growing conviction in its long-term prospects. The stock has gained over 56% in the past three months.
Let’s take a brief look at how all these stocks perform on TipRanks’ Stock Comparison Tool: